How are insurers coping with the increased demand for multi-use drugs like Wegovy and Ozempic? In an article by Insurance Business America, AHP Partner and Consulting Actuary, Greg Warren shares his insights from an actuarial perspective on the evolving pharmaceutical landscape and discuss the questions many plan sponsors are likely asking themselves when it comes to coverage of these drugs.
